Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg
administered twice a day orally versus a placebo as a modifying treatment of the disease in
patients with the progressive forms of Multiple Sclerosis (MS).
The principal outcome is to determine the efficacy, of andrographolide in retarding the
progression of brain atrophy in patients with progressive forms of MS.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Innobioscience SpA
Collaborators:
Pontificia Universidad Catolica de Chile Universidad Austral de Chile University of Chile